Sherlock Biosciences is an engineering biology company offering unparalleled breadth and versatility for diagnostic solutions.
Sherlock Biosciences is an engineering biology company offering unparalleled breadth and versatility for diagnostic solutions. It leverages engineering biology tools, including CRISPR and Synthetic Biology, to create molecular diagnostics that can rapidly deliver accurate results for a vast range of needs in virtually any setting. They combine the diagnostic power of SHERLOCK with that of a second core platform technology, Internal Splint-Pairing Expression Cassette Translation Reaction, or INSPECTRTM, to create diagnostic tools that are simple and easy to use in virtually any setting, and at the same time provide accurate, rapid and affordable results.SheSherlock Biosciences was founded in 2019 and is headquartered in Cambridge, Massachusetts, United States.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Nov 29, 2022 | Grant | — | 1 | — | — | Detail |
Mar 8, 2022 | Series B | $80M | 6 | Novalis LifeSciences | — | Detail |
Jan 1, 2022 | Series Unknown | $1.98M | 1 | Alameda Research | — | Detail |
May 21, 2020 | Grant | $7.50M | 1 | Open Philanthropy Project | — | Detail |
Apr 23, 2019 | Series A | $31M | 3 | Northpond Ventures | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Novalis LifeSciences | Yes | Series B |
Alameda Research | Yes | Series Unknown |
Open Philanthropy Project | Yes | Grant |
Bill & Melinda Gates Foundation | — | Grant |
Albany Capital | — | Series B |
Catalio Capital Management | — | Series B |
Good Ventures | — | Series B |
Illumina Ventures | — | Series B |
Northpond Ventures | — | Series B |
Baidu Ventures | — | Series A |